Involvement of Senescence and Mitochondrial Fission in Endothelial Cell Pro-Inflammatory Phenotype Induced by Angiotensin II

Masashi Miyao(Kyoto University), Satoru Eguchi(University of South Florida), Stephanie Cicalese(Temple University), Tatsuo Kawai(University of Iowa), Michael Boyer(Chris O’Brien Lifehouse), Hannah Cooper(Temple University), Rosario Scalia(Thomas Jefferson University), Steven J. Forrester(Emory University), Katherine J. Elliott(Cornell University), Victor Rizzo(University of Iowa), Ryohei Kuroda(Temple University), Tomoki Hashimoto(Obayashi (Japan))
International Journal of Molecular Sciences
April 28, 2020
10.3390/ijms21093112
Cited by 43

Related Papers

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
|Circulation Research|2018|2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k